Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

David Alan Campbell net worth and biography

David Campbell Biography and Net Worth

Founder, President & CEO of Janux Therapeutics

David founded Janux in 2017 to develop tumor-specific cancer therapeutics in order to improve patient safety and efficacy for this important class of drugs. David brings more than 25 years of seasoned executive management, company creation, and successful partnering coupled with broad disease and drug development expertise to his role as Janux CEO. Prior to Janux, David served as CSO or CEO of multiple drug discovery and development companies that have created numerous clinical programs and partnerships with large pharma. These include Sitari (celiac disease) partnered with GSK, Afraxis (oncology) partnered with Genentech, and RQx (anti-bacterial) partnered with Genentech. Before that, David was Senior Vice President of Drug Discovery and Development at Phenomix, where he guided the discovery and development of clinical programs to treat diabetes and hepatitis C. Earlier in his career, David held positions of increasing responsibility in biotech at Affymax and large pharma at Bayer Pharmaceuticals. As director at Bayer, his group contributed to multiple clinical programs in oncology, obesity, and diabetes.

David earned a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College, and received post-doctoral training under then University of California, Berkeley professor: Dr. Peter Schultz.

What is David Alan Campbell's net worth?: The estimated net worth of David Alan Campbell is at least $13.76 million as of December 3rd, 2024. Dr. Campbell owns 242,054 shares of Janux Therapeutics stock worth more than $13,755,929 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Campbell may own. Additionally, Dr. Campbell receives an annual salary of $1,040,000.00 as Founder, President & CEO at Janux Therapeutics. Learn More about David Alan Campbell's net worth.
How old is David Alan Campbell?: Dr. Campbell is currently 64 years old. There are 5 older executives and no younger executives at Janux Therapeutics. Learn More on David Alan Campbell's age.
What is David Alan Campbell's salary?: As the Founder, President & CEO of Janux Therapeutics, Inc., Dr. Campbell earns $1,040,000.00 per year. Learn More on David Alan Campbell's salary.
How do I contact David Alan Campbell?: The corporate mailing address for Dr. Campbell and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on David Alan Campbell's contact information.
Has David Alan Campbell been buying or selling shares of Janux Therapeutics?: In the last ninety days, David Alan Campbell has sold $3,633,500.00 in Janux Therapeutics stock. Most recently, David Alan Campbell sold 15,000 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a transaction totalling $1,005,000.00. Following the completion of the sale, the chief executive officer now directly owns 242,054 shares of the company's stock, valued at $16,217,618. Learn More on David Alan Campbell's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), and Andrew Meyer (Chief Business Officer). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, Janux Therapeutics insiders bought shares 1 times. They purchased a total of 1,200,000 shares worth more than $53,700,000.00. During the last year, insiders at the sold shares 14 times. They sold a total of 3,460,610 shares worth more than $185,833,665.79. The most recent insider tranaction occured on December, 3rd when CEO David Alan Campbell sold 15,000 shares worth more than $1,005,000.00. Insiders at Janux Therapeutics own 29.4% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 12/3/2024.

David Alan Campbell Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2024	Sell	15,000	$67.00	$1,005,000.00	242,054
11/25/2024	Sell	25,000	$51.60	$1,290,000.00	257,054
10/28/2024	Sell	25,000	$53.54	$1,338,500.00	282,054
9/27/2024	Sell	25,000	$46.31	$1,157,750.00	307,054

David Alan Campbell Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $56.83

$55.63

$59.72

50 Day Range

MA: $53.89

$40.18

$66.84

2 Week Range

Now: $56.83

$7.79

$71.71

Volume

1,251,821 shs

Average Volume

788,634 shs

Market Capitalization

$2.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.29

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

David Campbell Biography and Net Worth

What is David Alan Campbell's net worth?

How old is David Alan Campbell?

What is David Alan Campbell's salary?

How do I contact David Alan Campbell?

Has David Alan Campbell been buying or selling shares of Janux Therapeutics?

Who are Janux Therapeutics' active insiders?

Are insiders buying or selling shares of Janux Therapeutics?